• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

沙特阿拉伯多发性硬化症患者的计划生育:专家共识

Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus.

作者信息

Al Jumah Mohammed, Al Malik Yaser, AlKhawajah Nuha M, Saeedi Jameelah, AlThubaiti Ibtisam, Bohlega Saeed, Bunyan Reem F, Cupler Edward J, ElBoghdady Ahmed, Hassan Ahmed, Ali Eman Nassim, Clerico Marinella

机构信息

Neurology Department, King Fahad Medical City, Riyadh, Saudi Arabia.

College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

出版信息

Mult Scler Int. 2021 Feb 15;2021:6667006. doi: 10.1155/2021/6667006. eCollection 2021.

DOI:10.1155/2021/6667006
PMID:33628508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7899766/
Abstract

More than half of all patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) are women of childbearing age. Raising a family is an important life goal for women in our region of the world. However, fears and misconceptions about the clinical course of relapsing-remitting MS (RRMS) and the effects of disease-modifying drugs (DMDs) on the foetus have led many women to reduce their expectations of raising a family, sometimes even to the point of avoiding pregnancy altogether. The increase in the number of DMDs available to manage RRMS and recent studies on their effects in pregnancy have broadened management options for these women. Interferon beta now has an indication in Europe for use during pregnancy (according to clinical need) and can be used during breastfeeding. Glatiramer acetate is a further possible option for women with lower levels of RRMS disease activity who are, or about to become, pregnant; natalizumab may be used up to 30 weeks in patients with higher levels of disease activity. Where possible, physicians need to support and encourage women to pursue their dream of a fulfilling family life, supported where necessary by active interventions for RRMS that are increasingly evidence based.

摘要

沙特阿拉伯王国(KSA)超过半数的多发性硬化症(MS)患者为育龄期女性。组建家庭是我们这个世界区域女性的一项重要生活目标。然而,对复发缓解型多发性硬化症(RRMS)临床病程以及疾病修正药物(DMDs)对胎儿影响的恐惧和误解,导致许多女性降低了组建家庭的期望,有时甚至完全避免怀孕。用于治疗RRMS的DMDs数量增加以及近期关于其在孕期影响的研究,拓宽了这些女性的管理选择。干扰素β目前在欧洲有孕期使用指征(根据临床需要),并且可在哺乳期使用。对于RRMS疾病活动程度较低且正在怀孕或即将怀孕的女性,醋酸格拉替雷是另一种可能的选择;对于疾病活动程度较高的患者,那他珠单抗可在孕30周前使用。在可能的情况下,医生需要支持并鼓励女性追求充实的家庭生活梦想,必要时通过对RRMS越来越多基于证据的积极干预措施来提供支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c5/7899766/58590a62a653/MSI2021-6667006.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c5/7899766/58590a62a653/MSI2021-6667006.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c5/7899766/58590a62a653/MSI2021-6667006.001.jpg

相似文献

1
Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus.沙特阿拉伯多发性硬化症患者的计划生育:专家共识
Mult Scler Int. 2021 Feb 15;2021:6667006. doi: 10.1155/2021/6667006. eCollection 2021.
2
Rituximab for relapsing-remitting multiple sclerosis.利妥昔单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
3
Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region.多发性硬化症患者的疾病修正药物与计划生育:来自海湾地区的共识性叙述综述
Neurol Ther. 2020 Dec;9(2):265-280. doi: 10.1007/s40120-020-00201-8. Epub 2020 Jun 20.
4
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
5
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.采用多准则决策分析(MCDA)评估克拉屈滨治疗复发缓解型多发性硬化症的获益风险。
Clin Ther. 2019 Feb;41(2):249-260.e18. doi: 10.1016/j.clinthera.2018.12.015.
6
Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus.卡塔尔复发性缓解型多发性硬化症的管理:专家共识。
Curr Med Res Opin. 2020 Feb;36(2):251-260. doi: 10.1080/03007995.2019.1669378. Epub 2019 Oct 7.
7
Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.那他珠单抗治疗复发缓解型多发性硬化症:来自沙特阿拉伯的经验
Clin Neuropharmacol. 2018 Nov/Dec;41(6):199-201. doi: 10.1097/WNF.0000000000000305.
8
Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.在沙特阿拉伯,与基于干扰素的疗法相比,口服药物治疗复发缓解型多发性硬化症的成本效益。
Ann Saudi Med. 2017 Nov-Dec;37(6):433-443. doi: 10.5144/0256-4947.2017.433.
9
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.干扰素β与醋酸格拉替雷治疗复发缓解型多发性硬化症的对比
Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.
10
Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.富马酸二甲酯作为多发性硬化症患者一线治疗的有效性——一项单中心真实世界观察性研究
Pol Merkur Lekarski. 2019 Dec 27;47(282):221-225.

引用本文的文献

1
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice.海湾地区关于使用克拉屈滨片治疗复发型多发性硬化症的实用建议:最新真实世界证据对临床实践的影响
Neurol Ther. 2024 Oct;13(5):1321-1335. doi: 10.1007/s40120-024-00650-5. Epub 2024 Aug 3.
2
The Effect of Multiple Sclerosis on Family Planning Among Saudi Families.多发性硬化症对沙特家庭计划生育的影响。
Cureus. 2023 Nov 24;15(11):e49353. doi: 10.7759/cureus.49353. eCollection 2023 Nov.
3
Psychosocial Basis of Human Sufferings and Poverty in Patients with Neurological and Psychiatric Disorders.

本文引用的文献

1
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide.来氟米特(多发性硬化症药物特立氟胺的母体化合物)治疗患者的妊娠结局。
Reprod Toxicol. 2020 Aug;95:45-50. doi: 10.1016/j.reprotox.2020.04.073. Epub 2020 May 11.
2
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.免疫重建疗法还是持续免疫抑制用于治疗复发缓解型多发性硬化症活动期患者?一项叙述性综述。
Neurol Ther. 2020 Jun;9(1):55-66. doi: 10.1007/s40120-020-00187-3. Epub 2020 Apr 15.
3
Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
神经和精神疾病患者痛苦与贫困的社会心理基础
Med Res Arch. 2023 May;11(5). doi: 10.18103/mra.v11i5.3919. Epub 2023 May 20.
4
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.用于复发型多发性硬化症治疗的克拉屈滨片安全性专家叙述性综述
Neurol Ther. 2023 Oct;12(5):1457-1476. doi: 10.1007/s40120-023-00496-3. Epub 2023 Jun 29.
5
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.免疫重建疗法在法国复发型多发性硬化症管理中的地位:专家共识
Neurol Ther. 2023 Apr;12(2):351-369. doi: 10.1007/s40120-022-00430-z. Epub 2022 Dec 24.
6
[Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.].[多发性硬化症。哺乳期。婴儿。计划生育。产后。疾病修正治疗。]
Rev Neurol. 2023 Jan 1;76(1):21-30. doi: 10.33588/rn.7601.2022404.
当代多发性硬化症队列中与妊娠相关的复发和母乳喂养。
Neurology. 2020 May 5;94(18):e1939-e1949. doi: 10.1212/WNL.0000000000009374. Epub 2020 Apr 13.
4
Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.克拉屈滨片与复发缓解型多发性硬化症:医生所需了解内容的实用叙述性综述
Neurol Ther. 2020 Jun;9(1):11-23. doi: 10.1007/s40120-020-00177-5. Epub 2020 Feb 13.
5
Pregnancy and Motherhood Concerns Surrounding Women with Multiple Sclerosis: A Qualitative Content Analysis.多发性硬化症女性的妊娠与母亲身份相关问题:一项质性内容分析
Int J Community Based Nurs Midwifery. 2020 Jan;8(1):2-11. doi: 10.30476/IJCBNM.2019.73900.0.
6
Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study.沙特阿拉伯多发性硬化症患病率上升:一项描述性研究。
BMC Neurol. 2020 Feb 8;20(1):49. doi: 10.1186/s12883-020-1629-3.
7
Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.计划妊娠导致芬戈利莫德停药后多发性硬化症活动反弹:易患因素分析。
Mult Scler Relat Disord. 2020 Feb;38:101483. doi: 10.1016/j.msard.2019.101483. Epub 2019 Oct 30.
8
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.芬戈莫德反弹:临床经验与管理考量综述
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.
9
Exploring the outcome of multiple sclerosis among Saudi adult patients. A single-centered cross-sectional study at King Abdulaziz Medical City in Riyadh, Saudi Arabia.探索沙特成年患者的多发性硬化症结局。在沙特阿拉伯利雅得的阿卜杜勒阿齐兹国王医疗城进行的一项单中心横断面研究。
Neurosciences (Riyadh). 2019 Jul;24(3):168-175. doi: 10.17712/nsj.2019.3.20180034.
10
Pregnancy and Family Planning in Multiple Sclerosis.多发性硬化症患者的妊娠与计划生育
Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745.